KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Deferred Tax Liability: 2020-2025

Historic Non-Current Deferred Tax Liability for Castle Biosciences (CSTL) over the last 4 years, with Sep 2025 value amounting to $3.2 million.

  • Castle Biosciences' Non-Current Deferred Tax Liability fell 23.18% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 23.18%. This contributed to the annual value of $1.6 million for FY2024, which is 93.49% down from last year.
  • Latest data reveals that Castle Biosciences reported Non-Current Deferred Tax Liability of $3.2 million as of Q3 2025, which was up 3.71% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Non-Current Deferred Tax Liability registered a high of $27.1 million during Q4 2022, and its lowest value of $206,000 during Q1 2024.
  • Over the past 3 years, Castle Biosciences' median Non-Current Deferred Tax Liability value was $1.2 million (recorded in 2024), while the average stood at $3.9 million.
  • Within the past 5 years, the most significant YoY rise in Castle Biosciences' Non-Current Deferred Tax Liability was 856.92% (2024), while the steepest drop was 93.49% (2024).
  • Over the past 5 years, Castle Biosciences' Non-Current Deferred Tax Liability (Quarterly) stood at $19.6 million in 2021, then spiked by 38.56% to $27.1 million in 2022, then decreased by 9.00% to $24.7 million in 2023, then tumbled by 93.49% to $1.6 million in 2024, then decreased by 23.18% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.1 million for Q2 2025, and $837,000 during Q1 2025.